Clostridium difficile: An update for the primary care clinician

Southern Medical Journal

Volumn 103, Issue 9, 2010, Pages 896-902

  Salkind, Alan R ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; diarrhea; primary care; review

Indexed keywords

METRONIDAZOLE; RIFAMPICIN; RIFAXIMIN; VANCOMYCIN; ANTIINFECTIVE AGENT; PROBIOTIC AGENT;

CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; HAND WASHING; HUMAN; PATHOGENESIS; PRIMARY MEDICAL CARE; REVIEW; CROSS INFECTION; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; MICROBIOLOGY; PATIENT CARE; PEPTOCLOSTRIDIUM DIFFICILE; PRIMARY HEALTH CARE; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX;

ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HANDWASHING; HUMANS; METRONIDAZOLE; PATIENT ISOLATION; PRIMARY HEALTH CARE; PROBIOTICS; RECURRENCE; SEVERITY OF ILLNESS INDEX; VANCOMYCIN; HAND DISINFECTION;

EID: 77956392634     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181eab419     Document Type: Review

References (41)

1. Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008;46(suppl 1):S4-S11.
2. Riggs MM, Sethi AK, Zabarsky TF, et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostrid-ium difficile strains among long-term care facility residents. Clin Infect Dis 2007;45:992-998.
3. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostrid-ium difficile infection. [Review.] Clin Infect Dis 2008;46(suppl 1):S12-S18.
4. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007;13:1417-1419.
5. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-353.
6. O'Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:1219-1227.
7. Elixhauser A, Jhung M. Clostridium difficile-associated disease in U.S. Hospitals, 1993-2005. Healthcare cost and utilization project. Statistical brief #50 2008. Search: Clostridium difficile. Available at: www.hcup-us.ahrq.gov. Accessed January 5, 2009.
8. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-472.
9. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-1260.
10. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents 2009;33(suppl 1):S42-S45.
11. Surveillance for community-associated Clostridium difficile-Connecti-cut, 2006. Mor Mortal Wkly Rep 2008;57:340-343.
12. Hirschhorn LR, Trnka Y, Onderdonk A, et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994;169:127-133.
13. Dial S, Kezouh A, Dascal A, et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008;179:767-772.
14. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-associated disease in populations previously at low risk\four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:1201-1205.
15. Bartlett JG, Onderdonk AB, Cisneros RL, et al. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 1977;136:701-705.
16. Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009;458:1176-1179.
17. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353: 2433-2441.
18. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-1084.
19. Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 2005;173:1037-1042.
20. Wanahita A, Goldsmith EA, Musher DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002; 34:1585-1592.
21. Anand A, Glatt AE. Clostridium difficile infection associated with an-tineoplastic chemotherapy: a review [review]. Clin Infect Dis 1993;17: 109-113.
22. Pierce PF Jr, Wilson R, Silva J Jr, et al. Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. J Infec Dis 1982;145:269-274.
23. Peterson LR, Robicsek A. Does my patient have Clostridium difficile infection? Ann Intern Med 2009;151:176-179.
24. Gerding D, Muto C, Owens RJ. Treatment of Clostridium difficile infection. Clin Infect Dis 2008;46(suppl 1):S32-S42.
25. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clos-tridium difficile in clinical samples. J Clin Microbiol 2009;47:373-378.
26. FDA approves rapid DNA test to detect Clostridium difficile infection. Search: rapid DNA test to detect Clostridium difficile infection. Available at: www.medscape.com. Accessed January 5, 2010.
27. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005;5:549-557.
28. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005;54:101-111.
29. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vanco-mycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45: 302-307.
30. Pepin J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic? Clin Infect Dis 2008; 46:1493-1498.
31. Dendukuri N, Costa V, McGregor M, et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005;173:167-170.
32. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clos-tridium difficile disease. J Med Microbiol 2005;54:905-906.
33. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 2007;35:131-137.
34. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006;49:640-645.
35. Borody TJ. "Flora power"\fecal bacteria cure chronic C. difficile diarrhea. Am J Gastroenterol 2000;95:3028-3029.
36. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36:580-585.
37. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-427.
38. Musher DM, Logan N, Bressler AM, et al. Nitazoxanide versus vanco-mycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41-e46. Available at: http://www. journals.uchicago.edu/toc/ cid/current. Accessed January 4, 2009.
39. Dryden B, Mohammed R, Chasen-Taber S, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Costridium difficile-associated diarrhoea [abstract 0464]. Presented at 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 2008.
40. Wilcox MH, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;54:168-172.
41. O'Connor KA, Kingston M, O'Donovan M, et al. Antibiotic prescribing policy and Clostridium difficile diarrhoea. Q J Med 2004;97:423-429.